Teligent, Inc. Announces Second Quarter 2021 Earnings Report and Provides Business Update
|–||Update on FDA Inspection of Buena Facility|
|–||Assessing New Growth Opportunities in Injectables|
|–||Conference Call to Be Held on August 16, 2021 at 8:30 am Eastern Standard Time|
|–||Dial in:||(877) 407-0792 US Toll Free Number|
|(201) 689-8263 International Number|
|Confirmation Number: 13721972|
“Product demand in our core business was impacted by a combination of factors, including remediation-related activities, the ongoing effects of the COVID-19 pandemic, and modest generic pricing erosion seen within the topicals segment,” said
Second Quarter 2021 - Financial Highlights
- Total revenues were
$10.4 millionfor the three-months ended June 30, 2021versus $13.6 millionin Prior Period for 2020. The decrease was driven primarily by lost contract volume due to remediation-related activities, the continuing effects of the COVID-19 pandemic, and modest product price erosion due to generic competition.
- Cost of revenues increased
$2.1 millionto $13.1 millionfor the Current Period, versus $11.1 millionfor the Prior Period mainly attributable to the cost of inventory reserves as well as the ongoing cost of remediation and period expenses combined with lower absorption.
- Selling, general and administrative expenses of
$5.7 millionfor the Current Period, increased from $5.0 millionfor the Prior Period. The increase was primarily due to higher professional fees resulting from our debt restructuring, offset slightly by a decrease in personnel related costs.
- Product development and research expenses were
$2.2 millionfor the Current Period, versus $1.9 millionfor the Prior Period. The increase was primarily due to API related expenses offset by decreases in personnel costs, outside testing and pilot batch expenses.
- Net loss attributable to common stockholders decreased by
$1.5 million, or 10%, to $12.9 million for the Current Period, from $14.3 million for the Prior Period. The decrease was primarily due to a decrease in interest and other expenses of $4.5 millionand a $4.6 milliondecrease in change in the fair value of derivative liabilities. Operating loss has increased by $6.3 millionfrom period-to-period to $10.7 millionas a result of lower net product revenues and higher overall costs and expenses discussed above.
Full Year 2021 Financial Guidance
As previously noted in our first quarter 2021 earnings release, the Company will not be providing financial guidance for the year ending December 31, 2021 at this time or in the immediate term. There are a number of factors which weigh on our inability to provide such financial guidance, including, but not limited to, the continuing macroeconomic volatility triggered by the COVID-19 global pandemic and its continued impact on the Company’s business plans, our efforts to resolve the Warning Letter issued by the FDA in November 2019, as well as the currently on-going inspection and reinspection of our facilities and the unknown results from such inspection and reinspection. An additional factor contributing to this inability is the uncertainty regarding the timing for the FDA to conduct the pre-approval inspection of our newly constructed sterile injectable manufacturing facility in Buena,
FDA Warning Letter Update
As previously reported, based on management’s assessment of our remediation efforts at the
Prior to our informing the FDA of our inspection readiness, the Company was informed by the FDA that it would commence a periodic Current Good Manufacturing Practices (“CGMP”) inspection and reinspection to follow-up on FDA Warning Letter remediation actions in mid-July. This inspection and reinspection remain ongoing and no formal communication from the FDA to the Company regarding the outcome or providing the final results of the inspection and reinspection has been issued, nor is the timing of such communications determinable at this time. Therefore, until such time as the results of the FDA’s inspection and reinspection are formally made available to us and we have had ample opportunity to review and analyze the same with our consultants and advisors we will have no further comment on this matter.
COVID-19 Response Summary
In alignment with the directives in the state of New Jersey, as a Pharmaceutical manufacturing facility, we are considered "essential". During the COVID-19 Public Health Emergency and State of Emergency in order to continue to supply our products to the patients that need them, we maintained our manufacturing operations and monitored conditions in order to maintain a safe workplace for our employees. The Company has taken several preventative measures to help ensure business continuity, while maintaining safe and stable operations. We have implemented social distancing measures on-site at our manufacturing facility to protect employees and our products. Our employees are provided daily personal protective equipment upon their arrival to the site and we have implemented temperature monitoring services at our newly established single point of entrance. We have also implemented a more frequent sanitization process of the facility. As the Public Health Emergency, State of Emergency and restrictions have abated, we have implementing a phased ‘return to office’ protocol under which we will maintain social distanced workspace and continue to sanitize our facilities.
About Teligent, Inc.
Teligent is a specialty generic pharmaceutical company. Our mission is to be a leading player in the specialty generic prescription drug market. Learn more on our website www.teligent.com.
This press release includes certain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, plans, objectives, expectations and intentions, and other statements contained in this press release that are not historical facts and statements identified by words such as “plan,” “believe,” “continue,” “should” or words of similar meaning. Factors that could cause actual results to differ materially from these expectations include, but are not limited to: our inability to meet current or future regulatory requirements in connection with existing or future ANDAs; our inability to achieve profitability; our failure to obtain FDA approvals as anticipated; our inability to execute and implement our business plan and strategy; the potential lack of market acceptance of our products; our inability to protect our intellectual property rights; changes in global political, economic, business, competitive, market and regulatory factors; and our inability to successfully complete future product acquisitions. These statements are based on our current beliefs or expectations and are inherently subject to various risks and uncertainties, including those set forth under the caption “Risk Factors” in Teligent, Inc.’s most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other periodic reports we file with the Securities and Exchange Commission. Teligent, Inc. does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise, except as required by law.
|CONSOLIDATED BALANCE SHEETS|
|(in thousands, except share and per share information)|
|Cash and cash equivalents||$||22,626||$||5,946|
|Accounts receivable, net||9,849||11,257|
|Prepaid expenses and other receivables||1,761||3,486|
|Total current assets||51,501||44,291|
|Property plant and equipment, net||15,928||16,131|
|Intangible assets, net||19,161||22,964|
|LIABILITIES AND STOCKHOLDERS’ DEFICIT|
|Capital lease obligation, current||476||436|
|Total current liabilities||12,568||23,121|
|Series C Senior Secured Convertible Notes, net of debt discount and debt issuance costs (face of $- and
|Series D Senior Convertible Notes, net of debt discount and debt issuance costs (face of
|Revolver, net of debt issuance costs (face of
|2023 Term Loan, net of debt issuance costs (face of
|Deferred tax liability||196||190|
|Other long term liabilities||4,663||4,914|
|Series D Preferred Stock,
|Additional paid-in capital||197,372||135,218|
|Accumulated other comprehensive loss||(3,282||)||(2,094||)|
|Total stockholders’ deficit||(58,887||)||(110,152||)|
|Total liabilities, mezzanine equity and stockholders' deficit||$||90,419||$||87,788|
|CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS|
|(in thousands, except shares and per share information)|
|Three months ended
||Six months ended
|Costs and expenses:|
|Cost of revenues||13,136||11,084||25,935||19,694|
|Selling, general and administrative expenses||5,735||4,989||12,007||11,706|
|Product development and research expenses||2,227||1,880||3,690||3,680|
|Total costs and expenses||21,098||17,953||41,656||43,453|
|Other income expense:|
|Foreign currency exchange gain (loss)||785||2,125||(1,307||)||528|
|Interest and other expense, net||(2,989||)||(7,520||)||(7,108||)||(13,396||)|
|Gain on debt restructuring||-||-||22,439||-|
|Change in fair value of derivative liabilities||-||(4,591||)||(3,186||)||(5,849||)|
|Loss before income tax expense||(12,869||)||(14,353||)||(10,686||)||(41,137||)|
|Income tax (benefit) expense||(3||)||(21||)||27||31|
|Loss attributable to common shareholders||$||(12,866||)||$||(14,332||)||$||(10,713||)||$||(41,168||)|
|Loss per share|
|Basic and diluted loss per share||$||(0.14||)||$||(2.56||)||$||(0.14||)||$||(7.50||)|
|Weighted average shares of common stock outstanding:|
|Basic and diluted shares||93,410,017||5,593,557||76,037,735||5,491,554|
|CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Six months ended
|Cash flows from operating activities:|
|Changes in operating assets and liabilities||478||(85||)|
|Net cash used in operating activities||(17,415||)||(11,143||)|
|Net cash used in investing activities||(229||)||(2,369||)|
|Net cash provided by financing activities||34,392||3,371|
|Effect of exchange rate on cash and cash equivalents||(68||)||484|
|Net increase (decrease) in cash, cash equivalents and restricted cash||16,680||(9,657||)|
|Cash, cash equivalents and restricted cash at beginning of period||6,712||16,182|
|Cash, cash equivalents and restricted cash at end of period||$||23,392||$||6,525|
Source: Teligent, Inc.